Last updated: March 3, 2026
What is NDC 62332-0624?
NDC 62332-0624 refers to a specific drug product listed in the National Drug Code directory. This NDC code corresponds to Tirzepatide (brand name: Mounjaro), a novel once-weekly injectable therapy approved for type 2 diabetes and weight management.
Market Overview
Therapeutic Area and Indications
Tirzepatide targets type 2 diabetes mellitus (T2DM) and obesity. Its dual mechanism of action—combining GLP-1 and GIP receptor agonism—positions it against established GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and dulaglutide (Trulicity).
Market Size and Growth Drivers
- T2DM Market: Valued at approximately $80 billion globally in 2022, with a projected CAGR of 7% until 2027 [1].
- Obesity Market: Estimated at $17 billion annually, expected to grow at 15% CAGR driven by increasing obesity prevalence [2].
Competitor Landscape
- Semaglutide (Ozempic, Wegovy): Dominates at approximately 42% market share among GLP-1 therapies.
- Dulaglutide (Trulicity): Holds about 20% in T2DM segment.
- Liraglutide (Victoza): 10% market share.
Position of Tirzepatide
Clinical trials show Tirzepatide offers superior glycemic control and weight reduction compared to Semaglutide. The SURPASS trials demonstrate:
- HbA1c reduction: 2.1% vs. 1.5% with semaglutide.
- Weight loss: Up to 22 pounds at higher doses.
FDA approval received in May 2022 for T2DM; its approval for obesity is pending.
Price Projections
Current Pricing
- Tirzepatide (Mounjaro): Wholesale acquisition cost (WAC) is approximately $982 per month for the 15 mg dose (average for T2DM indication) [3].
- Market competitors: Semaglutide WAC around $945 per month; dulaglutide around $850 per month.
Forecasted Pricing Trends
- Early indications suggest prices for Tirzepatide may decrease marginally as biosimilars or generic options emerge, expected within 5-7 years post-patent expiration.
- For the next 3 years, maintaining current WAC levels is probable, given the drug's superior efficacy and limited direct competition.
Cost Impact and Payers
- Insurers are likely to favor Tirzepatide for its efficacy, influencing formulary placements.
- Patient copayments could range from $20-70/month depending on insurance coverage.
Market Penetration and Revenue Estimates
- By 2025, Tirzepatide could secure approximately 20-25% of the GLP-1 market in T2DM.
- Projected revenues: Based on a conservative 15 million eligible patients globally, assuming 20% uptake, 3 million patients at $982/month yields over $35 billion annually.
Regulatory and Policy Factors
- Pending FDA decisions on obesity indication may alter the market landscape.
- CMS and private insurers' formulary decisions will impact access and utilization.
Key Factors Affecting Price Projections
- Patent protections remain until 2032, limiting biosimilar competition.
- Introduction of biosimilars or alternative formulations.
- Competitive dynamics with emerging therapies such as oral semaglutide and SGLT2 inhibitors.
- Changes in healthcare policies influencing drug pricing and reimbursement.
Summary of Financial Outlook
| Year |
Estimated Market Share |
Projected Revenue (USD) |
Key Assumptions |
| 2023 |
10-12% |
$3.6 billion |
Initial market adoption, premium price |
| 2024 |
15-20% |
$7.2 billion |
Increased clinician familiarity |
| 2025 |
20-25% |
$11.4 billion |
Expanded indication approval |
Conclusion
NDC 62332-0624 (Tirzepatide) holds a strong position as a high-efficacy therapy within the T2DM and obesity markets. Its premium pricing is expected to remain stable over the next three years, with substantial revenue potential driven by efficacy advantages. Long-term, patent expirations and biosimilar development could pressure prices, impacting market share and revenues.
Key Takeaways
- Tirzepatide provides superior metabolic control over current GLP-1 treatments.
- Prices likely to stay near current levels for 3 years, with potential decrease post-patent.
- The drug could capture up to a quarter of the market share in the coming years.
- Competitive landscape remains aggressive, with biosimilars and new entrants in development.
- Policy and payer strategies will influence access and pricing levels.
FAQs
Q1. When will Tirzepatide face biosimilar competition?
Biosimilar versions will likely enter between 2026 and 2028, depending on patent law and regulatory processes.
Q2. How does Tirzepatide compare price-wise to its competitors?
Current WAC is similar to semaglutide, approximately $970-$985/month. Pricing strategies may shift as market dynamics evolve.
Q3. Will Tirzepatide's approval for obesity impact its market share?
Yes. Approval would expand its target patient population, increasing revenue potential and market share.
Q4. Is Tirzepatide covered widely by insurance?
Insurance coverage is increasing due to its efficacy profile, but copay levels vary. Commercial plans are more likely to reimburse than some Medicaid plans.
Q5. What are the primary risks to Tirzepatide’s market valuation?
The main risks include regulatory delays for new indications, market entry of biosimilars, pricing pressures, and adverse trial data.
References
[1] IQVIA. (2022). Global Prescription Drug Market Data.
[2] Grand View Research. (2022). Obesity Market Size, Share & Trends.
[3] GoodRx. (2023). Tirzepatide Pricing.
